Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-139 vs Eylea in nAMD
NCT07844148Phase 3Recruiting
- Sponsor
- Generium
- Start
- Jul 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Generium. Primary endpoint: Change from baseline in Best-Corrected Visual Acuity at 8 weeks. Started Jul 2026; status: recruiting.
02
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07844148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07844148.